CoChat

Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study

Fava, Maurizio, Ménard, François, Davidsen, Charlotte Kampp, Baker, Ross A. · 2016 · The Journal of Clinical Psychiatry

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To evaluate the effects of adjunctive brexpiprazole on symptoms of irritability in patients with major depressive disorder (MDD). METHODS: Patients diagnosed with MDD according to DSM-IV-TR criteria who had inadequate response to antidepressant treatment continued treatment with their current antidepressant for 2 weeks. Patients still having inadequate response, and with irritability, received 6 weeks of open-label treatment with their current antidepressant at the same dose and adjunctive brexpiprazole (target dose: 3 mg/d). Brexpiprazole was discontinued at week 6, and the patients continued with their antidepressant until week 10. Changes from baseline to week 6 and week 6 to week 10 were analyzed. RESULTS: This study was conducted between October 7, 2013, and July 30, 2014. Fifty-four patients were treated with adjunctive brexpiprazole. At week 6, clinically relevant improvements were observed in Sheehan Irritability Scale total (-21.1) and item 1 (irritable mood) (-3.5) scores, Kellner Symptom Questionnaire total (-24.4) and anger-hostility subscale (-7.7) scores, and 30-item Inventory of Depressive Symptomatology, clinician version (IDS-C₃₀), item 6 (irritable mood) score (-1.2). More (15 patients) stopped than developed (5 patients) anger attacks during treatment, as measured by the Anger Attacks Questionnaire. The Clinical Global Impressions-Severity of Illness score improved (-1.4), as did the depressive symptoms (IDS-C₃₀ total score, -17.8; Kellner Symptom Questionnaire depression subscale score, -7.7; and Montgomery-Asberg Depression Rating Scale total score, -14.2). Irritability symptoms worsened after brexpiprazole discontinuation, assessed at week 10. Adjunctive brexpiprazole was well tolerated. CONCLUSIONS: Adjunctive treatment with brexpiprazole may represent a strategy for patients with MDD and inadequate response to antidepressant treatment who have symptoms of irritability. TRIALS REGISTRATION: ClinicalTrials.gov identifier: NCT01942785.

Overview

Integrity signals

Registry

Crossref · 10.4088/jcp.15m10470

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 23 references

Cited by

See all 24

Metadata

Authors
Fava, M., Ménard, F., Davidsen, C. K., & Baker, R. A.
Affiliations
  • Lundbeck (Denmark) (DK)
  • Otsuka (United States) (US)
Venue
The Journal of Clinical Psychiatry
Published
2016-07-05
Volume
77
Issue
12
Pages
1695-1701
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2460591166
Cited by
23
References
23
Citations by year
2026: 2 · 2025: 1 · 2023: 2 · 2022: 3 · 2021: 1 · 2020: 3 · 2019: 3 · 2018: 2 · 2017: 4 · 2016: 1
FWCI
2.70
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords
brexpiprazole, major depressive disorder, irritability, adjunctive therapy, inadequate response to antidepressants, irritable mood, anger attacks, antidepressant non-response, treatment discontinuation
MeSH terms
Adult, Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Irritable Mood, Male, Middle Aged, Thiophenes, Quinolones, Outcome Assessment, Health Care, Serotonin Agents, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study. https://app.cochat.ai/papers/10.4088/jcp.15m10470
The paper
Fava, M., Ménard, F., Davidsen, C. K., & Baker, R. A. (2016). Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.15m10470

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.